ER Wait Time | Door To Provider: 70 minutes | If this is a life-threatening emergency, call 911.

On June 21, 2016, Mayo Clinic Proceedings published an important article on men’s health and testosterone.

In 2015 the FDA compelled label changes for all testosterone products marketed in the United States. This label change effectively limited indications for prescribing testosterone. Physicians and patients have been concerned and even confused about diagnosing and treating low testosterone.

The Sexual Medicine Society of North America convened an expert panel to evaluate the existing evidence on low testosterone. In particular, the panel focused on low testosterone associated with low or normal gonadotropin levels. This common clinical scenario accounts for most men with low testosterone and has been named Adult-Onset Hypogonadism (AOH). After reviewing the evidence, the panel concluded that men who present with AOH often have other common disease states like diabetes or metabolic syndrome. The panel notes that men with AOH should be counseled regarding the benefits and risks of treatment with testosterone.

The panel detailed a rigorous diagnostic process to ensure that men with AOH are accurately identified. In addition, the panel noted that men who are treated with testosterone must be followed regularly for indications of benefit and for adverse events.

Several authors discuss Adult-Onset Hypogonadism and how it differs from classic diagnoses of Primary and Secondary Hypogonadism.

Irwin Goldstein, MD, medical director of the sexual medicine program at Alvarado Hospital was among several national experts who contributed to the review and recommendations, published today in Mayo Clinic Proceedings.

To interview Dr. Goldstein, editor-in-chief of Sexual Medicine Reviewse-mail us.